Literature DB >> 1613715

Fever, hepatitis and acute interstitial nephritis in a patient with rheumatoid arthritis. Concurrent manifestations of azathioprine hypersensitivity.

E Meys1, J P Devogelaer, A Geubel, J Rahier, C Nagant de Deuxchaisnes.   

Abstract

We describe a patient with rheumatoid arthritis (RA) who developed hypersensitivity after 3 weeks of therapy with azathioprine with fever, jaundice and renal insufficiency. A percutaneous liver biopsy was compatible with hypersensitivity hepatitis. During azathioprine rechallenge, the symptoms recurred within a few days, consistent with the diagnosis of an acute hypersensitivity reaction. This report is the first to describe the association of an azathioprine induced hypersensitivity simultaneously involving the liver and the kidneys, in the same patient with RA, with resurgence after rechallenge.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613715

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Use of thiopurines in inflammatory bowel disease: Safety issues.

Authors:  Anastasia Konidari; Wael El Matary
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

Review 2.  [Dosage and toxicity of antirheumatic drugs in renal insufficiency].

Authors:  S M Weiner; R Bergner
Journal:  Z Rheumatol       Date:  2015-05       Impact factor: 1.372

Review 3.  Renal manifestations in inflammatory bowel disease: a systematic review.

Authors:  Karen van Hoeve; Ilse Hoffman
Journal:  J Gastroenterol       Date:  2022-07-14       Impact factor: 6.772

Review 4.  Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.

Authors:  Alexander Teml; Elke Schaeffeler; Klaus R Herrlinger; Ulrich Klotz; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 5.577

5.  Renal involvement in paediatric inflammatory bowel disease.

Authors:  Mohamed Mutalib
Journal:  Pediatr Nephrol       Date:  2019-12-09       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.